(ECOG) performance status 0/1 and previously untreated, metastatic pancreatic adenocarcinoma were randomly assigned 1:2 to gemcitabine (1000 mg/m2 weekly seven times, 1 week rest, weekly three times q4weeks) or gemcitabine plus AGS-1C4D4 (48 mg/kg loading dose, then 24 mg/kg q3weeks IV)...
抗HUMAN PSCA (AGS-1C4D4) 单克隆抗体生产厂家 全球有 1家供应商抗 HUMAN PSCA (AGS-1C4D4) 单克隆抗体国内生产厂家 供应商联系电话电子邮件国家产品数优势度 武汉佰乐博生物技术有限公司027-65279366 18108604862products@biolabreagent.com中国981858
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Annals of oncology. 2013; 24:1792-1801.Wolpin BM, O'Reilly EM, Ko YJ, Blaszkowsky LS, Rarick M, Rocha-Lima CM, et al. Global...